CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in...

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Large cell lung carcinoma (LCLC), a subtype of non-small cell lung cancer (NSCLC), exhibits aggressive behavior and presents an unmet medical need.
• The protein kinase CK2 is implicated in various cancers, making it a potential therapeutic target.

Purpose of the Study:

• To investigate the efficacy of the anti-CK2 peptide CIGB-300 as a potential therapeutic agent against LCLC.
• To elucidate the molecular mechanisms underlying CIGB-300's action in an LCLC cell model.

Main Methods:

• Utilized NCI-H460 cells as a model for LCLC.
• Assessed CIGB-300's cytotoxicity and effects on cell cycle progression.
• Performed interactomics profiling to identify CIGB-300's protein targets.
• Investigated CIGB-300 binding to CK2 subunits using in vivo pull-down assays, immunoblotting, and confocal microscopy.
• Analyzed the impact of CIGB-300 on the phosphorylation and protein levels of S6 ribosomal protein (RPS6).

Main Results:

• NCI-H460 cells demonstrated high sensitivity to CIGB-300, with peak apoptosis observed at 6 hours.
• CIGB-300 treatment led to a slight impairment of the cell cycle in NCI-H460 cells.
• Interactomics analysis identified over 300 proteins involved in cancer-relevant biological processes targeted by CIGB-300.
• CIGB-300 showed preferential binding to the CK2α' catalytic subunit.
• Down-regulation of RPS6 phosphorylation and protein levels was observed 48 hours post-treatment.

Conclusions:

• NCI-H460 cells represent the most CIGB-300-sensitive solid tumor cell line reported to date.
• CIGB-300 exhibits significant anti-cancer activity in an LCLC model.
• The study uncovers novel insights into CK2 targeting by the CIGB-300 peptide, suggesting its potential as an anticancer therapeutic.